Study the effects of PLGA-PEG encapsulated Amphotericin B nanoparticle drug delivery system against Leishmania donovani

被引：51

作者：

Kumar, Rishikesh ^{[1
]}

Sahoo, Ganesh Chandra ^{[1
]}

Pandey, Krishna ^{[2
]}

Das, V. N. R. ^{[2
]}

Das, Pradeep ^{[1
,3
]}

机构：

[1] Rajendra Mem Res Inst Med Sci, Nanotechnol & Drug Discovery, Patna 800007, Bihar, India

[2] Rajendra Mem Res Inst Med Sci, Dept Clin Med, Patna 800007, Bihar, India

[3] Rajendra Mem Res Inst Med Sci, Dept Mol Biol, Patna 800007, Bihar, India

来源：

DRUG DELIVERY | 2015年 / 22卷 / 03期

关键词：

Amastigotes; amphotericin B; electron microscope; kala azar; nanometer; PLGA-PEG; promastigote; VISCERAL LEISHMANIASIS;

D O I：

10.3109/10717544.2014.891271

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drug delivery systems are a promising technology to increase poor solubility and bioavailability of compounds. Therefore we have developed PLGA-PEG encapsulated amphotericin B nanoparticles (NPs) drug delivery technology to increase the solubility of amphotericin B and target the macrophage of infected tissues during visceral leishmaniasis. The structural characterization by transmission electron microscopy and dynamic light scattering revealed the nano-size of the particle (30-35 nanometers). Fourier transform infrared spectroscopy confirmed the PLGA-PEG encapsulation. The mean cytotoxic assay (0.0803 + 0.0253) of extracellular promastigote of PLGA-PEG encapsulated amphotericin B is significantly lower than that of amphotericin B (0.1134 + 0.0153) and inhibition of amastigotes in the splenic tissue was significantly more than with conventional amphotericin B (93.02 + 6.63 versus 74.42 + 14.78). Amphotericin B encapsulated PLGA-PEG nanoparticles were found to be more effective than free amphotericin B in terms of therapeutic efficacy during in vitro and in vivo study.

引用

页码：383 / 388

页数：6

共 14 条

[1] ONE-SIDED ACTION OF AMPHOTERICIN-B ON CHOLESTEROL-CONTAINING MEMBRANES IS DETERMINED BY ITS SELF-ASSOCIATION IN THE MEDIUM [J].

BOLARD, J ;

LEGRAND, P ;

HEITZ, F ;

CYBULSKA, B .

BIOCHEMISTRY, 1991, 30 (23) :5707-5715

[2] Drug resistance in leishmaniasis [J].

Croft, SL ;

Sundar, S ;

Fairlamb, AH .

CLINICAL MICROBIOLOGY REVIEWS, 2006, 19 (01) :111-+

[3] Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation [J].

Gershkovich, Pavel ;

Wasan, Ellen K. ;

Lin, Molly ;

Sivak, Olena ;

Leon, Carlos G. ;

Clement, John G. ;

Wasan, Kishor M. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (01) :101-108

[4] Interaction of Leishmania with the host macrophage [J].

Handman, E ;

Bullen, DVR .

TRENDS IN PARASITOLOGY, 2002, 18 (08) :332-334

[5] Amphotericin B: New life for an old drug [J].

Hartsel, S ;

Bolard, J .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (12) :445-449

[6] Imported visceral leishmaniasis: Diagnostic dilemmas and comparative analysis of three assays [J].

Iqbal, J ;

Hira, PR ;

Saroj, G ;

Philip, R ;

Al-Ali, F ;

Madda, PJ ;

Sher, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (02) :475-479

[7] Preface nanoparticulate systems for improved drug delivery [J].

Kawashima, Y .

ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (01) :1-2

[8] LIPOSOMES AND NANOPARTICLES AS VEHICLES FOR ANTIBIOTICS [J].

KREUTER, J .

INFECTION, 1991, 19 :S224-S228

[9] Secretory pathway of trypanosomatid parasites [J].

McConville, MJ ;

Mullin, KA ;

Ilgoutz, SC ;

Teasdale, RD .

MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2002, 66 (01) :122-+

[10] Nanosuspensions as particulate drug formulations in therapy Rationale for development and what we can expect for the future [J].

Muller, RH ;

Jacobs, C ;

Kayser, O .

ADVANCED DRUG DELIVERY REVIEWS, 2001, 47 (01) :3-19

← 1 2 →